Trials / Terminated
TerminatedNCT01522196
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Anthera Pharmaceuticals · Industry
- Sex
- All
- Age
- 5 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Varespladib | 48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr. |
| OTHER | Placebo (Normal Saline) | 48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr. |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2012-01-31
- Last updated
- 2014-03-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01522196. Inclusion in this directory is not an endorsement.